Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – Here’s What Happened

Bavarian Nordic (OTCMKTS:BVNRY) saw unusually-strong trading volume on Thursday. Approximately 5,993 shares were traded during mid-day trading, an increase of 81% from the previous session’s volume of 3,305 shares. The stock last traded at $11.45 and had previously closed at $11.09.

Bavarian Nordic Stock Performance

The stock has a market cap of $2.74 billion, a PE ratio of 11.66 and a beta of 1.25. The company’s 50-day moving average price is $10.43 and its two-hundred day moving average price is $9.92.

Bavarian Nordic (OTCMKTS:BVNRY) last released its earnings results on Friday, August 21st. The company reported $0.46 EPS for the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%.The business had revenue of $316.47 million for the quarter.

Bavarian Nordic Company Profile

Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.

Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.